PharVision Advisers’s Accenture ACN Stock Holding History

PharVision Advisers’s Portfolio ACN Stock Details ACN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,221	Closed	-$381K	–	269
2025 Q1	$381K	Buy	+1,221	New	+$431K	0.53%	45

Other funds holding ACN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PharVision Advisers's ACN Position: Q2 2025 in Review

PharVision Advisers sold out of Accenture (ACN) in Q2 2025, closing a stake of 1,221 shares — an estimated $381K sold.

PharVision Advisers first reported a position in ACN in Q1 2025 and held it in 1 quarter. The position peaked at $381K in Q1 2025. 2,370 funds tracked by Wall St. Rank hold ACN as of Q2 2025.

PharVision Advisers reported no remaining Accenture position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 1,221 Accenture shares in Q2 2025, an estimated $381K.
PharVision Advisers first reported a position in Accenture in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Accenture position peaked at $381K in Q1 2025.
2,370 funds tracked by Wall St. Rank held Accenture as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.